Product ID: SQMIG15E2248
Global Magnesium Sulphate Market Size, Share, Growth Analysis, By Type(Heptahydrate, anhydrous), By Application(Fertilizer, medical) - Industry Forecast 2024-2031
Report ID:
SQMIG15E2248 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
65 |
Figures:
75
Global Magnesium Sulphate Market News
- In December 2021, B. Braun Medical Inc., a company specializing in infusion therapy and pain management, announced the introduction of a range of ready-to-use injectable drug products containing magnesium Sulphate. To ensure a reliable supply of this important drug used for preventing and controlling seizures associated with preeclampsia and eclampsia, the products are manufactured in Irvine, California.
- In November 2021, Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, obtained approval from the US FDA for its Abbreviated New Drug Application (ANDA) for the Generic Version of Magnesium Sulphate in Water for Injection. The approval covers doses of 4 g/50 mL (80 mg/mL), 4 g/100 mL (40 mg/mL), and 2 g/50 mL (40 mg/mL) in Non-PVC, Single-Patient Use Containers. Magnesium Sulphate Injection is used to prevent and control seizures in preeclampsia and eclampsia. The approval and launch of the generic version are expected to address supply issues of this essential medication listed on the ASHP drug shortage list.
- In April 2021, K+S Group finalized the divestment of its America's salt business associated with the Operating Unit Americas. The sale was completed to Stone Canyon Industries Holdings LLC, Mark Demetree, and Partners for a total price of USD 2.93 billion. This divestment represents a significant step for K+S Group in reducing its debt and aligning its focus on other core operations.
Global Magnesium Sulphate Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
